Dr. Sutphen Discusses Insurance Coverage of Genetic Counseling and Testing

Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

A quality improvement project improved the time to molecular testing for patients with newly diagnosed, metastatic non–small cell lung cancer.

Derazantinib, an FGFR inhibitor, was associated with a median progression-free survival (PFS) of 7.8 months in patients with FGFR2-positive intrahepatic cholangiocarcinoma.

The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.